Christie® CounterAct™ products with patented Care222® technology
CounterAct commercial UV disinfection fixtures contain Ushio Inc.’s patented Care222 lamps that emit far-UVC 222nm light that’s shown to significantly reduce surface pathogens in occupied and unoccupied indoor spaces. It’s the only far-UVC germicidal technology that may also be used around people, and the only with a proprietary filter that prevents longer UVC wavelengths from being emitted.
The entertainment industry faces extraordinary challenges as a result of the global pandemic, including closed venues and steep revenue declines. Audiences want to return, but the presence of pathogens is a major concern.
Manual cleaning requires professional cleaners and the repeated use of harsh chemicals, can only be performed when spaces are empty, its effects are temporary, and can’t continuously reduce pathogens.
CounterAct products with patented Care222 technology can be operated continuously even when people are around (in accordance with specified parameters), either alone or in-between manual cleanings.
CounterAct products contain patented Care222 lamps that emit filtered far-UVC light that has been shown in the lab to inactivate more than 99.7% of pathogens on surfaces like the SARS-CoV-2 coronavirus (the novel coronavirus that causes COVID-19) and may be used in occupied spaces.
Could CounterAct with Care222 help defend your venue?
We know ultraviolet (UV) light is highly effective in reducing pathogens. Businesses have long used germicidal UVC light to disinfect spaces. However, because the typical 254nm UVC wavelength presents a human health hazard, it can only be used where protected people are present.
Not all UVC light is created equal
CounterAct products contain patented Care222 lamps that emit far-UVC light, a sweet spot on the UV spectrum that is effective against reducing pathogens but may be used around people. And it’s the only technology with a proprietary filter that prevents longer UVC wavelengths from being emitted.
But don’t just take our word for it, download our white paper to discover the science and the studies behind the Care222 technology in our CounterAct products.
A study conducted by Kobe University researchers called Exploratory clinical trial on the safety and bactericidal effect of 222-nm ultraviolet C irradiation in healthy humans published in August 2020 in PLOS ONE suggests that the filtered far-UVC light emitted by Care222 modules reduces pathogens while people are present.
Yes! Here’s how: CounterAct products with patented Care222 technology emit far-UVC 222nm light that damages the RNA of pathogens like coronaviruses, leaving them unable to reproduce and infect us.
In a peer-reviewed study entitled Far-UVC light (222nm) efficiently and safely inactivates airborne human coronaviruses published in June 2020 in the journal Nature, researchers at Columbia University Irving Medical Center reported that 99.9% of aerosolized seasonal coronaviruses (that cause the common cold) were inactivated when exposed to far-UVC 222nm light for just 25 minutes.
A world-first: A study published in September 2020 in the American Journal of Infection Control by researchers at Hiroshima University entitled Effectiveness of 222-nm ultraviolet light on disinfecting SARS-CoV-2 surface contamination found that far-UVC 222nm light effectively reduced more than 99.7% of surface contamination of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.
Each CounterAct fixture contains two Care222 far-UVC excimer lamps with patented filters that significantly reduce pathogens like the SARS-CoV-2 coronavirus that causes COVID-19.
CounterAct products can be used throughout your venue – from your lobby and auditorium to your restrooms.
The patented Care222 modules used in our CounterAct products effectively inactivate pathogens, may be used when people are present, contain a proprietary filter, and are mercury-free.
CounterAct products with patented Care222 technology and proprietary filters emit far-UVC 222nm light that cannot penetrate healthy human skin when used in accordance with operational specifications
The patented far-UVC light that Care222 technology emits can reduce 99.9% of pathogens—including coronaviruses like the common cold and SARS-CoV-2, influenza, and bacteria.
CounterAct products with patented Care222 technology emit far-UVC 222nm light that damages the RNA of pathogens like coronaviruses for an extra layer of defense when used in combination with other measures like washing hands
As easy to install as traditional commercial lighting fixtures, with maintenance via an app
Able to operate over a wide range of ambient temperatures
Fixtures are available in black or white to fit existing color schemes
Instant on/off at full output power
Remote monitorable for easy programming and troubleshooting
Available in both AC and DC power configurations
Long-lasting - frequent on/off cycles don't affect lifetime
Easy-to-service for straightforward lamp changes
Flexible leasing options are available
News media can download CounterAct information here or contact pr@christiedigital.com
Learn more about far-UVC light disinfection and how it can help attractions add an extra layer of defense against pathogens. Attend Blooloop’s first live discussion of their new Innovation Sessions series February 3 at 10:30 am ET / 3:30 pm GMT.
Register for this free online event
Coronavirus is airborne. So how do we clean the air that we breathe? Martin Howe, Blooloop, examines the potential of far-UVC technology to help theme parks and attractions reopen in a post-COVID world.
Read more
Christie introduces groundbreaking far-UVC light fixture with patented Care222 technology for UV disinfection that may be used around people.
Read more
Every year, Fortune highlights companies that have made measurable social or environmental impact. The article features Ushio’s achievements in developing Care222 filtered far-UVC disinfection modules.
Read more
The first-ever research study conducted on the efficacy of far-UVC 222nm light against SARS-CoV-2 shows that just 3 mJ/cm2 of 222nm light effectively inactivated more than 99.7% of viable samples.
Read more
We know COVID-19 is spread indoors through droplets transmitted through the air. A breakthrough Columbia University study identifies far-UVC light as an effective COVID killer.
Read more
Kobe University Graduate School of Medicine and Ushio sutdy prove 222nm far-UVC is effective for irradiation and safe for humans
Read more
Scientists at Columbia University prove that 222nm far-UVC light inactivates 99.9% of coronaviruses.
Read more
Ushio Care222® Filtered Far UV-C Excimer
Video length - (06:08)
A new weapon in the fight against superbugs | David Brenner - TedTalk
Video length - (10:13)
Using the Power of Light: Preventing the Airborne Spread of Coronavirus
Video length - (01:36)
Can light stop the coronavirus? – David Brenner (TED Talk Daily Podcast)
Video length – (30:15)
Care222® Mercury-Free Far UV-C Excimer
Video length – (02:09)
Coronavirus: New Facts about Infection Mechanisms
Video length – (06:16)
The Care222® standard character mark and stylized logo mark are registered trademarks of Ushio America, Inc.’s patented technology, in the United States, European Union, and United Kingdom.
Christie CounterAct products with patented Care222 technology are not for use as or for medical devices or for use on humans or animals or to disinfect medical devices.
The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with American Conference of Governmental Industrial Hygienists (ACGIH) guidelines.
All references to “disinfect”, “disinfecting” and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority including the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency. Christie CounterAct products with patented Care222 technology are not medical devices and not to be used with or for medical devices. The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with American Conference of Governmental Institutional Hygienist (ACGIH) guidelines.
Product images as shown are for illustration purposes only. Actual product may vary due to product enhancement.
